Dr. Grint has served as a member of the Company’s board of directors since November 2015. Prior to becoming CEO of AmpliPhi, Dr. Grint was the President and CEO of Regulus Therapeutics, Inc., a company focused on the discovery and development of microRNA therapeutics, since June 2015. Dr. Grint has more than two decades of experience in biologics and small molecule development, including the successful commercialization of products in oncology, anti-infectives and immunology. Prior to his role at Regulus, he served as President of Cerexa, Inc. Dr. Grint has also served in senior management roles at Forest Research Institute, Kalypsys, Zephyr Sciences, Pfizer, IDEC Pharmaceuticals and Schering-Plough Corporation. He is a Fellow of the Royal College of Pathologists, and is a member of numerous professional and medical societies. He holds a degree from St. Mary’s College, University of London and a medical degree from St. Bartholomew’s Hospital College, University of London.
Mr. Martin has served as CFO since January 2016. Most recently, Mr. Martin served for three years as the CFO of Apricus Biosciences, a publicly-traded pharmaceuticals company. Prior to Apricus, he was CFO and interim CEO of BakBone Software, where he led the sale of the Company to Quest Software, and Senior Consultant to the CEO and Acting Chief Accounting Officer for Leap Communications, a $2B telecommunications company. Mr. Martin’s leadership experience also includes serving as CFO of Stratagene Corporation, sold to Agilent Technologies in 2007 for $240M and as controller for Gen-Probe, now a part of Hologic. Mr. Martin began his career at Deloitte, where he spent 10 years in the San Diego office and served as Senior Audit Manager. He is active in the San Diego community, including serving as past president of the San Diego Chapter of FEI (Financial Executives International), a committee member of the Corporate Directors Forum and as a member of the San Diego Holiday Bowl Committee. Mr. Martin holds a B.S. in Accounting from San Diego State University and is a certified public accountant.
Dr. Gaidamaka brings more than 25 years in the life sciences sector to AmpliPhi in his role as Vice President of Chemistry, Manufacturing and Control. Prior to joining AmpliPhi, he served as CEO and CSO of Personalized OncoTherapeutics Inc. He has also held executive R&D, product development and quality control roles at Pharma Green LLD, Merial, Sanofi Pasteur, Bioniche Life Sciences Inc. and Biopharm JSC. Dr. Gaidamaka was previously head of the Department of Immunopharmacology & Allergology at the All-Union Research Institute of Drug Chemistry and Technology, Ukraine. He received a Ph.D. in immunology and microbiology and D.V.M from the Kharkov State Veterinary Academy, Ukraine.
Dr. Morales has served as VP of Research since 2012. Prior to joining AmpliPhi, she served as the head scientist for Special Phage Services (SPS), a private biotechnology company focused on bacteriophage therapy. AmpliPhi merged with SPS in 2012 to take advantage of SPS’ leadership position in the bacteriophage industry. She has over 12 years of industrial experience developing bacteriophages for therapeutic purposes against a variety of pathogens in the agricultural field and veterinarian and human medicine. Dr. Morales received her Ph.D. in bacteriophage therapy from the University of Technology, Sydney, Australia; an M.Sc. in Applied Molecular Biotechnology from the University of Sydney and a B.S. in Microbiology from the University of Los Andes, Bogota, Colombia.
Dr. Furr brings over a decade of integrated product development and regulatory affairs experience to this new position at AmpliPhi. Prior to joining the Company, Dr. Furr served as Senior Director of Operations at Rho, Inc., a clinical research organization, where she also held leadership roles in regulatory affairs, integrated product development, program management and medical writing. Dr. Furr’s prior experience includes providing strategic and operational support throughout all phases of clinical development, including formal interactions and negotiations with regulatory authorities as well as submission of several biologics license applications and new drug applications with the U.S. Food and Drug Administration. She received a Ph.D. from Texas A&M University where she studied bacteriophage lifecycle and lysis mechanisms, biochemistry, and biophysics.